Protalix BioTherapeutics (PLX), Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label Trial Evaluating Pegunigalsidase

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Fo

CARMIEL, Israel, Feb. 23, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cellbased protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research focused healthcare Group (Chiesi Group), today announced positive topline results from the BRIGHT Phase III clinical trial evaluating pegunigalsidase alfa (PRX102), 2 mg/kg, administered every four weeks, for the potential treatment of Fabry disease. PRX102 is the... More